PRESS RELEASE
Biotechnology IXALTIS raises 8 million euros!
Archamps Technopole (74) and Toulouse (31), 26 May 2016. The French startup specialised in genito-urinary disorders will be able to take the second step in its development, dedicated to research into urinary incontinence. IXALTIS has just successfully completed its first fundraising round, securing eight million euros to be subscribed into instalments from international investors. IXALTIS has been created by renowned urology and pharmaceutical experts: Dr Philippe Lluel, Christian Chavy, Dr Roberto Gradnik and Professors Pascal Rischmann and Xavier Gamé. The startup has a Board of Directors made up of renowned leaders in the science, managerial and entrepreneurial fields and is assisted by a strategic advisory board comprising some of the world scientific leaders in urology. The main activity of the company is biopharmaceutical research and clinical development, specialising in genito-urinary diseases. IXALTIS acquired three molecules including Litoxetine IXA001 under exclusive licence from Sanofi, with strong evidence of efficacy in pre clinical trials convincing enough to start proof of concept/ Phase 2 in Urinary Incontinence. Potential estimated at several hundred million euros… IXALTIS was granted an OSEO loan of €2.8 M for the MAGENTA collaborative industrial research project dedicated to uro-genital diseases. The round A fundraising of eight million euros was subscribed by key players in the investment capital business: Irdinov, Ixo Private Equity, Principia and Sofimac. Pierre Olivier Goineau, current President of France Biotech also joined the round. The economic stakes are high, and the potential turnover is estimated at several hundred million euros. Urinary incontinence is a field in which medical needs are not being met and Litoxetine could offer a solution for many patients. The disorder affects 400 million people around the world, mainly women and a possible new therapeutic solution is of great interest to those researching treatments for this pathology. More information at: www.ixaltis.com
IXALTIS press office MEDIACOM Consulting Agency Contact: Thierry Barret +33 450 431 515 / + 41 22 342 10 10
IXALTIS SA office Contact: Nathalie de Valleuil +33 450 432 470 / +33 625 812 847 devalleuil@ixaltis.com
23 mai 2016